Hospital CUF Porto S.A. — Clinical Trial Site

41 Registered trials

22 Currently recruiting

Organisation

Hospital CUF Porto S.A.

Location

Porto, Portugal

Identifier

ORG-100041883

Address

Estrada Da Circunvalacao N 14341, 4100-180, Portugal

Departments

#2101: Serviço de Imunoalergologia
3404:Serviço de Oncologia
5001:Serviço de Oncologia
5802: Pneumologia
Allergology
Medical Oncology
N/A
NA
Neuropsychiatry
Oncology
Oncology Department
Pneumology Service
Service of Oncology
Serviço de Oncologia
Serviço Pneumologia
Unidade de Ensaios Clínicos

Clinical trials at this site (41)

Search interface

A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending

2023-509176-42-00 Obesity and T2D 11
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Pending

2025-520565-51-00 small cell lung cancer 5
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending

2025-523869-22-00 advanced or metastatic extrapulmonary neuroendocrine ca 5
Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of… Recruiting

2023-508547-51-00 Aetiological treatment of moderate-to-severe allergic r 5 2025-11-18
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm… Recruiting

2024-515853-48-00 advanced/metastatic non-squamous non-small cell lung ca 5 2025-09-05
A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting

2024-514459-14-00 Non-Small Cell Lung Cancer 4 2025-04-22
Volrustomig Priming Regimens Exploratory Phase II Platform Study Recruiting

2023-509482-20-00 Solid Tumors 4 2024-12-03
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 non-squamous non-small cell lung cancer 5 2024-06-06
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Large cell neuroendocrine carcinoma 4 2023-10-17
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com… Recruiting

2025-521284-12-00 Non-small cell lung cancer 5 2026-03-05
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting

2025-521124-29-00 Non-Small Cell Lung Cancer 10 2026-02-13
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting

2024-517553-26-00 Advanced ALK-positive non-small cell lung cancer (NSCLC 5 2025-11-12
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs… Recruiting

2024-518586-10-00 Non-Squamous Non-Small Cell Lung Cancer 10 2025-09-18
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A study to evaluate the efficacy and safety of QMF149 (indacaterol acetate/mometasone furoate) versus Budesonide in children from 6 to less … Recruiting

2022-501899-26-00 Asthma 5 2023-09-01
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes… Recruiting

2024-511246-39-00 Solid tumours with HER2 aberrations 1 2021-07-27